Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.48 |
| ▸ | TACR1 | P25103 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16565196 | 0.83 | SLC6A4 (0.52) | SLC6A4SLC6A3SLC6A2TACR1KCNH2 | |
| SCHEMBL19998537 | 0.82 | DRD2 (0.46) | SLC6A4SLC6A3SLC6A2TACR1CYP2D6 | |
| SCHEMBL21078004 | 0.82 | SLC6A4 (0.42) | SLC6A4SLC6A3SLC6A2TACR1KCNH2 | |
| SCHEMBL17886622 | 0.79 | SLC6A4 (0.41) | SLC6A4SLC6A3SLC6A2TACR1KCNH2 | |
| SCHEMBL27982226 | 0.77 | ALDH1A1 (0.44) | SLC6A4SLC6A3SLC6A2CYP2D6MEN1 | |
| SCHEMBL373790 | 0.75 | SLC6A4 (0.57) | SLC6A4SLC6A3SLC6A2TACR1CYP2D6 | |
| SCHEMBL21214320 | 0.74 | DRD3 (0.54) | SLC6A4SLC6A3SLC6A2MCHR1OPRM1 | |
| SCHEMBL5361649 | 0.74 | OPRM1 (0.51) | SLC6A4SLC6A2TACR1CYP2D6MEN1 | |
| SCHEMBL5962422 | 0.73 | OPRM1 (0.63) | MEN1POLBKMT2AOPRM1OPRD1 | |
| SCHEMBL973548 | 0.73 | MEN1 (0.52) | TACR1MEN1KMT2AOPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK1, JAK2, JAK3 | SLC6A4 3188/4885SLC6A3 2605/4885SLC6A2 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.